Yahoo Finance This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year
Insiders were net buyers of Lexaria Bioscience Corp.'s (NASDAQ:LEXX ) stock during the past year. That is, insiders bought more stock than they sold.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
View our latest analysis for Lexaria Bioscience
The Last 12 Months Of Insider Transactions At Lexaria Bioscience
Over the last year, we can see that the biggest insider purchase was by insider Wayne Boos for US$127k worth of shares, at about US$1.41 per share. We do like to see buying, but this purchase was made at well below the current price of US$2.14. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insiders At Lexaria Bioscience Have Bought Stock Recently
At Lexaria Bioscience,over the last quarter, we have observed quite a lot more insider buying than insider selling. We can see that insider Wayne Boos paid US$127k for shares in the company. But insider Wayne Boos sold shares worth US$39k. Insiders have spent more buying shares than they have selling, so on balance we think they are are probably optimistic.
Does Lexaria Bioscience Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 9.4% of Lexaria Bioscience shares, worth about US$2.7m, according to our data. We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Lexaria Bioscience Tell Us?
It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Lexaria Bioscience stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Lexaria Bioscience. At Simply Wall St, we've found that Lexaria Bioscience has 6 warning signs (3 are significant!) that deserve your attention before going any further with your analysis.
Of course Lexaria Bioscience may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
